Beroctocog alfa
- Generic Name
- Beroctocog alfa
- Brand Names
- Alphanate
- Drug Type
- Biotech
- CAS Number
- 9001-27-8
- Unique Ingredient Identifier
- 17RNR4H479
- Indication
Beroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in adult and pediatric patients with von Willebrand Disease in who desmopression is either ineffective or contraindicated. It is not indicated for patients with severe (i.e. type 3) von Willebrand Disease whom are undergoing major surgery.
- Associated Conditions
- Bleeding
- Associated Therapies
- Perioperative management therapy
Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 361
- Registration Number
- NCT02976753
- Locations
- 🇮🇹
Swedish Orphan Biovitrum Research Site, Padova, Italy
🇬🇧Swedish Orphan Biovitrum Reserach site, London, United Kingdom
🇪🇸Swedish Orphan Biovitrum research site, Alicante, Spain
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
- Conditions
- Congenital Bleeding DisorderHaemophilia B With InhibitorsHaemophilia A With Inhibitors
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT01561391
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Grifols Biologicals, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00323856
- Locations
- 🇵🇱
Oddzial Chorob Wewnetrznych i Hematologii, Poznan, Szkolna, Poland
🇵🇱Katedra i Klinika Hematologii Collegium Medicum UJ, Krakow, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.